Hainaan (Deutenzalutamide) – Prostate Cancer | HongKong DengYue Medicine

Deutenzalutamide Application Scope

• Advanced Prostate Cancer

• Hormone-sensitive or castration-resistant cases

  

Deutenzalutamide Characteristics

• Ingredients: Deutenzalutamide

• Properties:​ Oral small-molecule androgen receptor (AR) inhibitor

• Packaging Specification:​ 40 mg × 28 tablets/box

• Storage:​ Keep in a cool, dry place, protected from light

• Expiry Date: 24 months

• Executive Standard: ​As per national pharmacopeia/local NDA approval

• Approval Number: Under review, not yet assigned (NDA submitted to NMPA)

• Date of Revision: 2024

• Manufacturer: Suzhou NeuPharma

Guidelines for the Use of Hainaan

• Dosage and Administration:

  • Recommended Dose: 40 mg tablets, as per physician guidance

  • Administration: With or without food

  • Missed Dose:​ Take as soon as remembered; skip if almost time for next dose

• Adverse Reactions:

  • Common Adverse Reactions:

    • Fatigue

    • hot flush

    • decreased appetite

  • Serious Adverse Reactions:

    • Hepatic impairment,

    • seizure risk (rare)

      ​

• Contraindications: Known hypersensitivity to it or excipients

• Precautions:

  • Monitor liver function, avoid in patients with history of seizures

Hainaan Interactions

• Caution with CYP3A4 strong inducers/inhibitors

• Avoid combination with medications that lower seizure threshold

• Possible interactions with anticoagulants and certain antivirals

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.